Approximately 6 million out of the estimated 18 million newly diagnosed patients with cancer globally receive radiation therapy annually and 800,000 of those cancer patients receive radiation therapy in the United States.5,6 Physicians, patients, nonprofit organizations, hospitals, insurance companies and advocates of cancer patient support programs understand the economic costs and severe toll this damage to healthy tissue inflicts on patients already struggling to fight their cancer. 


BioCurity's technology and product candidates have the potential to significantly reduce radiation toxicity not just for newly diagnosed cancer patients but also for the many other cancer patients who receive radiation as part of their ongoing treatment for cancer. Indications currently being considered for clinical development include but are not limited to: breast, lung, head & neck, prostate and colorectal cancer.


BioCurity's proposed topical product is designed to prevent or mitigate radiation damage to healthy tissue of the skin. BioCurity's proposed IV product is designed to prevent or mitigate radiation damage to healthy tissue of multiple internal organs.   





1Ryan, Julie. “Ionizing Radiation: The Good, the Bad, and the Ugly”. J Invest Dermatol. 132 (2012): 985-993

2Bray, Fleta, et al. “Acute and Chronic Cutaneous Reactions to Ionizing Radiation Therapy.” Dermatol Ther. 6 (2016): 185-206

3Radvansky, Lauren, et al. “Prevention and Management of Radiation-Induced Dermatitis, Mucositis and Xerostomia.” Am J Health Syst Pharm. 12 (2013): 1025-1032

4Peach, Matthew, et al. “Systematic Review of the Relationship between Acute and Late Gastrointestinal Toxicity after Radiotherapy for Prostate Cancer.” Prostate Cancer. 15 (2015): 1-11

5IAEA Reports 2017, Radiotherapy in Cancer Care, Facing the Global Challenge

6"All Cancers. Source Globcan: 2018." International Agency for Research on Cancer. March 2019. Web 23. August 2019


Print Print | Sitemap
© Biocurity